



NGL Fine-Chem Limited

Regd. Office : 301, E - Square, Subhash Road, Vile Parle East, Mumbai 400057, Maharashtra, INDIA
Tel.: (+91 22) 26636450 Fax : 26108030 Email : info@nglfinechem.com CIN : L24110MH1981PLC025884, Website : www.nglfinechem.com

August 12, 2020

To,

Department of Corporate Service (DCS-CRD),
BSE Limited Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai — 400 001.

Sub: Outcome of the Board Meeting Dated 12th August, 2020.
Scrip Code: 524774

This is to inform you that the Third Meeting of the Board of Directors of NGL Fine-Chem Limited for the financial year 2020-2021 held at the registered office of the Company on Wednesday, August 12, 2020 at 3.30 p.m and concluded at 4.15 p.m approved the following:

Approved Unaudited Standalone & Consolidated Financial Results for the quarter ended 30th June, 2020 pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

We further enclose herewith the Limited Review Report on Standalone and Consolidated Financial Results issued by the Statutory Auditors of the Company.

The aforesaid results are also being disseminated on Company's website at www.nglfinechem.com.

Kindly take the same on your record and acknowledge receipt of the same.

Thanking You,

Yours truly,
FOR NGL FINE-CHEM Ltd



Pallavi Pednekar
Company Secretary & Compliance Officer
Membership No: A33498



MANEK & ASSOCIATES

CHARTERED ACCOUNTANTS

3, Shanti Kunj, 17, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

Off. # 2618 5110
2618 5137
Fax # 2618 4912
shailesh.manek@gmail.com
www.camanek.com

SHAILESH MANEK

B.Com.(Hons), Grad. C.W.A., F.C.A.

Review report to,
The Board of Directors,
NGL Fine-Chem Limited...

We have reviewed the accompanying statement of unaudited financial results of **M/s.NGL Fine-Chem Limited** for the period ended **June 2020**.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this financial statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India.

This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MANEK & ASSOCIATES
Chartered Accountants
Firm's Registration No.:126679W



Shailesh Manek
(SHAILESH MANEK)

Proprietor

MUMBAI

DATED: 12th August, 2020.

Membership Number: 034925
UDIN: 20034925AAAAHL1672



MANEK & ASSOCIATES

CHARTERED ACCOUNTANTS

3, Shanti Kunj, 17, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

Off. # 2618 5110

2618 5137

Fax # 2618 4912

shailesh.manek@gmail.com

www.camanek.com

SHAILESH MANEK

B.Com.(Hons), Grad. C.W.A., F.C.A.

Independent Auditor's Review Report

To,
The Board of Directors,
NGL Fine-Chem Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of M/s.NGL Fine-Chem Limited ("the Parent") and its subsidiary M/s.Macrotech Polychem Private Limited (the Parent and its subsidiary together referred to as "the Group", and its share of the net profit/loss) for the quarter ended 30th June 2020 and for the period from 01st April 2020 to 30th June 2020 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of M/s. Macrotech Polychem Private Limited, its wholly owned subsidiary.

MANEK & ASSOCIATES

5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MANEK & ASSOCIATES
Chartered Accountants
Firm's Registration No.:126679W



MUMBAI
DATED: 12th August, 2020

SLA Manek
(SHAILESH MANEK)
Proprietor
Membership Number: 034925
UDIN: 20034925AAAAHN2867

NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road, Vile Parle (East), Mumbai 400 057, Maharashtra, India.

CIN: L24110MH1981PLC025894

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2020

Particulars	Quarter ended				Year ended
	30.06.2020 (Unaudited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)	
I Revenue from Operations	4,236.83	3,544.36	4,069.91	15,169.64	
II Other Income	218.30	82.93	135.40	305.08	
III Total Revenue (I+II)	4,455.13	3,627.29	4,205.31	15,473.72	
IV Expenses :					
a) Cost of Material Consumed	1,769.88	2,012.31	1,594.89	6,975.20	
b) (Increase)/Decrease in stock in trade and work in progress	(79.70)	(594.39)	35.80	(538.52)	
c) Employee benefits expenses	539.89	597.60	586.81	2,403.94	
d) Finance Costs	60.22	60.44	48.39	225.52	
e) Depreciation and amortisation expenses	209.62	221.05	186.76	811.20	
f) Other expenses	662.10	1,299.69	1,007.52	4,389.15	
Total Expenses (IV)	3,162.01	3,596.70	3,460.17	14,266.49	
V Profit/(loss) before exceptional items and tax (III-IV)	1,293.12	30.59	745.14	1,207.23	
VI Exceptional Items	-	-	-	-	
VII Profit/(loss) Before Tax (V-VI)	1,293.12	30.59	745.14	1,207.23	
VIII Tax Expense					
a) Current Tax	(288.30)	(131.76)	(217.50)	(484.00)	
b) MAT Tax	-	-	-	(10.41)	
c) Prior Years	-	-	-	-	
d) Deferred Tax	(66.10)	81.26	(8.04)	120.71	
IX Profit/ (Loss) for the period from continuing operations (VII-VIII)	938.72	(19.91)	519.60	833.53	
X Other Comprehensive Income					
a. Gain/(Loss) on actuarial valuation of post employment benefits	(4.64)	(4.55)	(4.26)	(29.18)	
b. Deferred tax on above	1.17	1.15	1.24	7.34	
c. Other Comprehensive Income (Net of Tax)	(3.47)	(3.40)	(3.02)	(21.84)	
XI Total Comprehensive Income	935.25	(23.31)	516.58	811.69	
XII Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each)	308.90	308.90	308.90	308.90	
XXIII Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A	N.A	N.A	9,587.18	
XIV Earnings Per Share (EPS)					
a) Basic	₹ 15.19	₹ -0.32	₹ 8.41	₹ 13.49	
b) Diluted	₹ 15.19	₹ -0.32	₹ 8.41	₹ 13.49	

Notes:

- The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Wednesday, 12th August, 2020. These results were subjected to Limited Review by the Statutory Auditors of the Company.
- The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
- The consolidated results are for NGL Fine Chem Limited together with its 100% subsidiary Macrotech Polychem Private Limited.
- Previous period figures have been regrouped/rearranged wherever necessary.

Place: Mumbai
Date: 12-Aug-20


UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2020

Particulars	Quarter ended				Year ended
	30.06.2020 (Unaudited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)	
I Revenue from Operations	4,242.36	3,548.22	4,069.91	15,218.09	
II Other Income	225.36	90.76	135.40	335.55	
III Total Revenue (I+II)	4,467.72	3,638.98	4,205.31	15,553.64	
IV Expenses :					
a) Cost of Material Consumed	1,772.00	2,015.90	1,594.89	7,019.42	
b) (Increase)/Decrease in stock in trade and work in progress	(79.70)	(594.39)	35.80	(538.52)	
c) Employee benefits expenses	528.20	585.37	586.81	2,380.98	
d) Finance Costs	60.21	60.39	43.53	225.26	
e) Depreciation and amortisation expenses	186.67	185.82	174.62	726.56	
f) Other expenses	760.58	1,319.93	989.27	4,302.62	
Total Expenses (IV)	3,227.96	3,573.02	3,424.92	14,116.32	
V Profit/(loss) before exceptional items and tax (III-IV)	1,239.76	65.96	780.39	1,437.32	
VI Exceptional Items	-	-	-	-	
VII Profit/(loss) Before Tax (V-VI)	1,239.76	65.96	780.39	1,437.32	
VIII Tax Expense					
a) Current Tax	(265.00)	(131.76)	(217.50)	(484.00)	
b) MAT Tax	-	-	-	(10.41)	
c) Prior Years	(67.39)	80.15	(8.42)	119.46	
d) Deferred Tax	-	-	-	-	
IX Profit/ (Loss) for the period from continuing operations (VII-VIII)	867.37	14.35	554.47	1,060.37	
X Other Comprehensive Income					
a. Gain/(Loss) on actuarial valuation of post employment benefits	(4.61)	(4.55)	(4.26)	(29.18)	
b. Deferred tax on above	1.16	1.15	1.24	7.34	
c. Other Comprehensive Income (Net of Tax)	(3.45)	(3.40)	(3.02)	(21.84)	
XI Total Comprehensive Income	863.92	10.95	551.45	1,038.53	
XII Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each)	308.90	308.90	308.90	308.90	
XXIII Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A	N.A	N.A	9,811.59	
XIV Earnings Per Share (EPS)					
a) Basic	₹ 14.36	₹ 0.23	₹ 8.97	₹ 17.16	
b) Diluted	₹ 14.36	₹ 0.23	₹ 8.97	₹ 17.16	

Notes:

- The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Wednesday, 12th August, 2020. These results were subjected to Limited Review by the Statutory Auditors of the Company.
- The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
- Previous period figures have been regrouped/rearranged wherever necessary.

For and On behalf of Board of Directors



Rahul Nachane
Managing Director
DIN 00223346